Lilly's Foundayo shows potential to significantly lower future risks of diabetes and heart disease

Lilly’s oral GLP-1 drug Foundayo, orforglipron, demonstrated notable projected reductions in 10-year risks of type 2 diabetes and cardiovascular disease in a Phase 3 trial, highlighting its promise beyond weight management. Eli Lilly says its once-daily oral GLP-1 treatment Foundayo,…















